Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Shares Issued (2016 - 2024)

ImmunityBio (IBRX) has disclosed Shares Issued for 11 consecutive years, with $15.6 million as the latest value for Q3 2024.

  • Quarterly Shares Issued rose 524.68% to $15.6 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $15.6 million through Jun 2025, down 77.49% year-over-year, with the annual reading at $73.3 million for FY2024, N/A changed from the prior year.
  • Shares Issued for Q3 2024 was $15.6 million at ImmunityBio, down from $52.8 million in the prior quarter.
  • The five-year high for Shares Issued was $94.9 million in Q2 2021, with the low at -$131.5 million in Q4 2021.
  • Average Shares Issued over 5 years is $6.6 million, with a median of $860500.0 recorded in 2020.
  • The sharpest move saw Shares Issued plummeted 93.4% in 2022, then skyrocketed 41976.19% in 2024.
  • Over 5 years, Shares Issued stood at $400000.0 in 2020, then crashed by 32971.75% to -$131.5 million in 2021, then soared by 99.94% to -$74000.0 in 2022, then surged by 3478.38% to $2.5 million in 2023, then soared by 524.68% to $15.6 million in 2024.
  • According to Business Quant data, Shares Issued over the past three periods came in at $15.6 million, $52.8 million, and $14.1 million for Q3 2024, Q2 2024, and Q1 2024 respectively.